Generic Strontium Chloride Sr-89 Injection (Generic Metastron®) is an option to consider for cancer bone pain therapy. Generic Strontium Chloride Sr-89 Injection imitates the behavior of calcium and is preferentially absorbed by bone, concentrating at sites of painful metastatic bone disease. Generic Strontium-89 injection is a pure beta emitter, and selectively irradiates sites of primary and metastatic bone involvment with minimal irradiation of soft tissues distant from bone lesions. The presence of bone metastases should be confirmed prior to therapy.
When blastic osseous metastases are present, significantly enhanced localization of the radiopharmaceutical will occur with corresponding higher doses to the metastases compared with normal bones and other organs. Repeated administrations of Generic Strontium-89 Chloride should be based on an individual patient’s response to therapy. Physicians should use caution before prescribing Generic Strontium Chloride Sr-89 to patients with a platelet count below 60,000 or white blood cell counts below 2,400.
Although responses can vary, patients may experience a flare in bone pain for a period of 36 to 72 hours after the administration of Generic Strontium Chloride Sr-89, with pain relief typically beginning 7 to 20 days after injection. Uptake of strontium by bone occurs preferentially in sites of active osteogenesis; thus primary bone tumors and areas of metastatic involvement (blastic lesions) can accumulate significantly greater concentrations of strontium than surrounding normal bone.